Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan;10(1):59-68.
doi: 10.2217/14622416.10.1.59.

EGFR-targeted therapies in lung cancer: predictors of response and toxicity

Rebecca Suk Heist  1 , David Christiani
Affiliations
Review

EGFR-targeted therapies in lung cancer: predictors of response and toxicity

Rebecca Suk Heist et al. Pharmacogenomics. 2009 Jan.

Abstract

The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular tyrosine kinase inhibitors, such as erlotinib or gefitinib, or monoclonal antibodies such as cetuximab. A growing body of evidence is identifying potential molecular predictors of response and toxicity. This includes tumor-related molecular markers, such as EGFR mutation and copy number, as well as germline markers such as polymorphisms in EGFR or EGFR pathway-related genes. This review focuses on the current state of knowledge of predictors of response and toxicity to EGFR inhibitors in lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Mechanisms of action of anti-EGFR drugs
Inhibition of cancer cell proliferation and invasion, metastatsis and tumor-induced neoangiogenesis. Induction of cancer cell cycle arrest and potentiation of antitumor activity of cytotoxic drugs and radiotherapy. Reproduced with permission from [2].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp. Cell Res. 2003;284:31–53. - PubMed

    1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008;358:1160–1174. Excellent review article encompassing clinical use of EGF receptor (EGFR) inhibitors in oncology.

    1. Sheperd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 2005;353:123–132. Pivotal Phase III trial showing benefit of EGFR tyrosine kinase inhibitor (TKI) erlotinib in lung cancer.

    1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol. 2003;21:2237–2246. - PubMed
    1. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA. 2003;290:2149–2158. - PubMed

Publication types

MeSH terms